https://www.biospace.com/elevar-therapeutics-announces-camrelizumab-plus-rivoceranib-significantly-prolonged-overall-survival-and-progression-free-survival-versus-sorafenib-in-patients-with-unresectable-hepatocellular-carcinoma-during-phase-3-trial
Elevar Therapeutics, Inc. announced top-line results from the Phase 3 study of its drug candidate rivoceranib combined with camrelizumab versus sorafenib as a...
therapeuticsannouncescamrelizumabplusrivoceranib
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1128172/full
The treatment for relapsed/refractory peripheral T-cell lymphoma (r/r PTCL) is suboptimal. This open-label, multicenter, single-arm study aimed to investigat...
frontiersantitumoractivitysafetycamrelizumab